Clinical Sciences Core
临床科学核心
基本信息
- 批准号:10155400
- 负责人:
- 金额:$ 15.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-09 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAbbreviationsAcquired Immunodeficiency SyndromeAddressAgingAreaBehavioral SciencesBiologicalBiostatistics CoreCardiovascular DiseasesCaringChicagoCitiesClinicClinicalClinical DataClinical InformaticsClinical InvestigatorClinical ResearchClinical SciencesClinical assessmentsCollaborationsColorectalCommunitiesComputational TechniqueComputer AnalysisConduct Clinical TrialsDataDevelopmentDiagnosisDisciplineDiseaseEducational CurriculumElderlyElectronic Health RecordEndotheliumEpidemicFoundationsFunctional disorderFundingFutureGenitalGenitaliaGlossaryGoalsGrowthHIVHIV InfectionsHealthHealth systemHuman Subject ResearchInflammationInfrastructureInstitutionInstitutional Review BoardsLaboratoriesLesbian Gay Bisexual Transgender QueerLinkMachine LearningMentorsMissionMonitorMucous MembraneNational Heart, Lung, and Blood InstituteOlder PopulationOutcomeParticipantPatient Outcomes AssessmentsPatientsPersonsPopulationPredictive AnalyticsProcessProgram DevelopmentProviderPublic HealthReportingResearchResearch PersonnelResearch SupportResource InformaticsResourcesRiskSECTM1 geneScientistServicesSiteSleep DisordersSocial SciencesSpecial PopulationSpecimenStudy SectionTechnologyTissuesTonsilTranslational ResearchTreatment EffectivenessUnited States National Institutes of HealthUniversitiesUpdateViralViral PathogenesisVulnerable Populationsadjudicateantiretroviral therapybasecare providerscareer developmentclinical decision supportclinical phenotypeclinical practicecommunity organizationscomorbiditycomputing resourcescytokinedata warehousedigitaleHealthimplementation scienceimprovedindexinginnovationmembermicrobiomeoperationpre-exposure prophylaxisprogramsreactive hyperemiarecruitrepositoryresearch studyscreening programservice providerssuccesstool
项目摘要
PROJECT SUMMARY
THIRD COAST CFAR CORE C: CLINICAL SCIENCES CORE (CSC)
In 2017, new HIV infections in Chicago decreased somewhat, and 92% of persons diagnosed with HIV were
linked to care within 12 months of diagnosis. However, major problems remain. Only 36% of persons living with
HIV (PLWH) in 2017 were retained in care, and only 48% achieved viral suppression. In addition, successes of
antiretroviral therapy (ART) have led to a rising population of older PLWH, which has made aging-related
comorbidities a proximate threat to well-suppressed PLWH and ultimately an increasing public health challenge.
Thus, the needs to improve real-world effectiveness of treatments, as well as HIV prevention, continue. The
Clinical Sciences Core (CSC) will intensify its support of research that addresses these problems, building on
infrastructure and linkages that we have created within and between Northwestern University (NU) and the
University of Chicago (UC). An expanding group of community organization partners also increases reach to
service providers, now notably including Howard Brown Health (HBH) that has expanded sites to areas of most
need and has a long commitment to the health of the LGBTQ community in Chicago. Offering CSC expertise
and services across disciplines and institutions is central to our mission and supports the development of new
scientific partnerships. This expertise includes human subjects research on streamlining ART and studying
aging-associated comorbidities and inflammation. Our accomplished and dynamic Clinical Informatics Group
(CIG) will continue advancing researcher access to sophisticated techniques for computation, analyses of
Electronic Health Record (EHR)-derived data, and emerging digital tools for research participants. The CSC also
emphasizes disseminating research findings and best practices, as well as engaging with community-based
clinics and HIV screening programs. The long-term goal of the CSC is to significantly increase the number of
outstanding clinical investigators, and the trans-disciplinary resources available to them, in order to fuel
discoveries that will propel us towards the end of the HIV epidemic. The CSC’s specific aims to reach this goal
are to: 1) support clinical research that interacts with HIV-infected and at-risk participants, and/or obtains and
studies clinical data and specimens from them; 2) catalyze and support new research on non-AIDS
comorbidities, including clinical phenotyping and pathophysiology of inflammation and accelerated aging in HIV;
3) expand research collaborations and linkages among study participants, clinical HIV researchers, HIV care
providers, other implementation partners and trainees. In the next project period, the CSC commits to expanding
the scope and impact of research on non-AIDS comorbidities among PLWH on ART as a major contributor to
TC CFAR’s Overall aim 2. Each of the CSC specific aims contributes to Overall aim 2 on non-AIDS comorbidities,
and the intent is to increase the CSC users’ trans-disciplinary research on aging and comorbidities in HIV.
项目概要
第三海岸 CFAR 核心 C:临床科学核心 (CSC)
2017年,芝加哥新发艾滋病毒感染人数有所下降,92%的艾滋病毒确诊者
然而,只有 36% 的患者仍存在严重问题。
2017 年艾滋病病毒感染者 (PLWH) 被保留在护理中,只有 48% 实现了病毒抑制。
抗逆转录病毒治疗(ART)导致老年感染者数量不断增加,这使得与衰老相关的疾病
合并症对受到良好抑制的艾滋病病毒感染者构成直接威胁,并最终成为日益严峻的公共卫生挑战。
因此,提高现实世界治疗有效性以及艾滋病毒预防的需求仍然存在。
临床科学核心 (CSC) 将加强对解决这些问题的研究的支持
我们在西北大学 (NU) 内部以及之间创建的基础设施和联系
芝加哥大学 (UC) 的社区组织合作伙伴群体不断扩大,也扩大了影响范围。
服务提供商,现在特别包括 Howard Brown Health (HBH),该公司已将站点扩展到大多数地区
需要并长期致力于芝加哥 LGBTQ 社区的健康,提供 CSC 专业知识。
跨学科和机构的服务是我们使命的核心,并支持新的开发
这种专业知识包括关于简化 ART 和学习的人类受试者研究。
与衰老相关的合并症和炎症。我们经验丰富且充满活力的临床信息学小组。
(CIG) 将继续推动研究人员获得复杂的计算、分析技术
CSC 还提供来自电子健康记录 (EHR) 的数据以及新兴的数字工具。
强调传播研究成果和最佳实践,以及与社区合作
CSC 的长期目标是显着增加诊所和艾滋病毒筛查项目的数量。
优秀的临床研究人员以及他们可用的跨学科资源,以推动
这些发现将推动我们终结艾滋病毒流行。CSC 的具体目标是实现这一目标。
是为了: 1) 支持与 HIV 感染者和高危参与者相互作用的临床研究,和/或获得和
2)促进和支持非艾滋病的新研究
合并症,包括艾滋病毒炎症的临床表型和病理生理学以及加速衰老;
3) 扩大研究参与者、临床艾滋病毒研究人员、艾滋病毒护理之间的研究合作和联系
在下一个项目期间,CSC 承诺扩大规模。
艾滋病病毒感染者非艾滋病合并症的研究范围和影响对抗逆转录病毒治疗的主要贡献者
TC CFAR 的总体目标 2。每个 CSC 具体目标都有助于实现关于非艾滋病合并症的总体目标 2,
其目的是增加 CSC 用户对衰老和艾滋病毒合并症的跨学科研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Babafemi O Taiwo其他文献
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
吸入干扰素-β1a (SNG001) 在成人轻度至中度 COVID-19 中的安全性和有效性:一项随机、对照、II 期试验
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:15.1
- 作者:
P. Jagannathan;K. Chew;M. Giganti;Michael D. Hughes;C. Moser;Mark J. Main;P. D. Monk;A. Javan;Jonathan Z Li;Courtney V. Fletcher;Caitlyn McCarthy;David A Wohl;Eric S. Daar;Joseph J Eron;Judith Currier;Upinder Singh;Davey M. Smith;William A Fischer;K. Chew;David (Davey) Smith;Eric S. Daar;David A Wohl;Judith Currier;Joseph J Eron;Michael D. Hughes;M. Giganti;J. Ritz;L. Hosey;Jhoanna Roa;Nilam Patel;Kelly Colsh;Irene Rwakazina;Justine Beck;Scott F. Sieg;Jonathan Z Li;Courtney V. Fletcher;William A Fischer;Teresa H. Evering;Rachel Bender Ignacio;Sandra Cardoso;Katya Corado;N. Jilg;Alan S. Perelson;Sandy Pillay;C. Riviere;Babafemi O Taiwo;Jane Gottesman;M. Newell;Susan Pedersen;J. Dragavon;Cheryl Jennings;Brian Greenfelder;W. Murtaugh;Jan Kosmyna;Morgan Gapara;A. Shahkolahi;G. Pierone;Juliana Elliott;Jeffrey M. Jacobson;Leila Hojat;Julie Pasternak;Jonathan Berardi;Celine Arar;Yevgeniy Bukhman;Manish Jain;Eugene Bukhman;Sadia Shaik;T. Hatlen;Kelly Dooley;Becky Becker;Adaliah Wilkins;Jose Pérez;Eloy Roman;Heriberto Fernández;Keila Hoover;James Renfroe;Mauney Weldon;Genei Bougher;Carlos D. Malvestutto;Heather Harber;Robyn Cicarella;Gene Neytman;Jack Herman;Craig Herman;Mariam Aziz;Joan Swiatek;Divya Pathak;Madhu Choudhary;Jennifer Sullivano;O. Osiyemi;Myriam Izquierdo;Odelsey Torna;Aleen Khodabakhshian;Samantha Fortier;Constance A Benson;Steven Hendrickx;Rosemarie Ramirez;Anne Luetkemeyer;Suzanne Hendler;Dennis Dentoni;Mario Castro;L. Spikes;Chase Hall;Jonathan Oakes;A. Loftis;Pablo Tebas;William R Short;Sarah McGuffin;Chris Jonsson;Rachel Presti;Alem Haile - 通讯作者:
Alem Haile
Primary Human Immunodeficiency Virus
原发性人类免疫缺陷病毒
- DOI:
- 发表时间:
2002 - 期刊:
- 影响因子:0
- 作者:
Babafemi O Taiwo;Charles B. Hicks - 通讯作者:
Charles B. Hicks
Prevalence of depression among people living with HIV in rural hospitals in South-Western Nigeria-Association with clinico-demographic factors
尼日利亚西南部乡村医院艾滋病毒感染者抑郁症患病率与临床人口因素的关系
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:2.2
- 作者:
W. A. Adedeji;Qing Ma;Abiodun Muhammed Raji;Raymond Cha;Olaniran Mudasiru Rasaki;Alan Hutson;Babafemi O Taiwo;Man E Charurat;O. B. Yusuf;F. Fehintola;O. Gureje;Gene D. Morse - 通讯作者:
Gene D. Morse
Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
尼日利亚两个 SARS-CoV-2 谱系同时快速扩张,传染性增强
- DOI:
10.1101/2021.04.09.21255206 - 发表时间:
2021-04-17 - 期刊:
- 影响因子:0
- 作者:
E. Ozer;L. Simons;O. M. Adewumi;Adeola A Fowotade;E. Omoruyi;J. Adeniji;Taylor J Dean;Babafemi O Taiwo;J. Hultquist;R. Lorenzo - 通讯作者:
R. Lorenzo
Antiretroviral Therapy: Darunavir: An Overview of an HIV Protease Inhibitor Developed to Overcome Drug Resistance
抗逆转录病毒疗法:达芦那韦:为克服耐药性而开发的 HIV 蛋白酶抑制剂概述
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Babafemi O Taiwo;Charles B. Hicks - 通讯作者:
Charles B. Hicks
Babafemi O Taiwo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Babafemi O Taiwo', 18)}}的其他基金
Expansion of SARS-CoV-2 Testing Supplement, Chicago Clinical Trials Unit
芝加哥临床试验中心 SARS-CoV-2 检测补充的扩展
- 批准号:
10166472 - 财政年份:2020
- 资助金额:
$ 15.05万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10228282 - 财政年份:2018
- 资助金额:
$ 15.05万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10600549 - 财政年份:2018
- 资助金额:
$ 15.05万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10468148 - 财政年份:2018
- 资助金额:
$ 15.05万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10252943 - 财政年份:2018
- 资助金额:
$ 15.05万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
9903485 - 财政年份:2013
- 资助金额:
$ 15.05万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
10462158 - 财政年份:2013
- 资助金额:
$ 15.05万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
10349429 - 财政年份:2013
- 资助金额:
$ 15.05万 - 项目类别: